The National Institutes of Health has updated its Strategic Plan for NIH Research to Cure Hepatitis B, a roadmap for ending the hepatitis B epidemic, focused on developing a cure as well as improved strategies for vaccination, screening and follow-up care. The revised plan incorporates lessons from the COVID-19 pandemic and recent advances in technology.
Submit a Media Request
Contact the NIAID News & Science Writing Branch.
Education:
M.D., University of Cagliari Medical School, Italy
Education:
M.P.H., 2002, Johns Hopkins School of Public Health
M.D.C.M., 1994, McGill University
B.Sc., University of Toronto
Languages Spoken: French
Education:
Ph.D., The Rockefeller University
Specialty(s): Infectious Disease, Internal Medicine
Education:
M.Sc., 1970, University of Notre Dame, IN
M.D., 1974, Northwestern University, Evanston, IL
Submit a Media Request
Contact the NIAID News & Science Writing Branch.
Hepatitis B is a serious liver infection caused by the hepatitis B virus (HBV).
For most people, Hepatitis B resolves on its own, but for others, it develops into a chronic infection. Hepatitis B can be prevented through vaccination, but no cure is available for those chronically infected. Chronic infection often leads to cirrhosis and liver cancer.
This module examines the structure and life cycle of HBV. Targeting specific components of the viral life cycle is key to development of a cure. Below is a list of resources to support this module.